Systemic adjuvant therapy is regularly recommended for patients diagnosed with invasive breast cancer based on risk of recurrence and likelihood of benefit from therapy. Progress in molecular biology has resulted in the identification and improved understanding of molecular markers that may have prognostic and predictive value for patients with breast cancer. HER2 (human epidermal growth factor receptor 2) is one of the best characterized of these markers and now plays a critical role in patient management.
KeywordsOverall Survival Left Ventricular Ejection Fraction Human Epidermal Growth Factor Receptor National Comprehensive Cancer Network National Comprehensive Cancer Network
Funding partially provided by the Breast Cancer Research Foundation.
- 10.Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523–30.PubMedGoogle Scholar
- 13.Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 Study Group. J Clin Oncol. 2005;23(19):4265–74.PubMedCrossRefGoogle Scholar
- 14.Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat. 2006;100(Suppl 1):S103.CrossRefGoogle Scholar
- 17.Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.PubMedGoogle Scholar
- 22.Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):6S.Google Scholar
- 24.Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(Suppl 1):S5.Google Scholar
- 25.Clinical Trials website. Maintained by the United States National Institutes of Health: National Library of Medicine. National Library of Medicine. 2007. Available at http://www.clinicaltrials.gov. Accessed October 2007.
- 29.Robert N, Loesch D, Lindquist D. A randomized, phase II trial of weekly paclitaxel vs. weekly paclitaxel + carboplatin for first-line metastatic breast cancer. Breast Cancer Res Treat. 2003;77:534.Google Scholar
- 30.Robert N, Leyland-Jones B, Asmar L, et al. Randomised phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Proc Am Soc Clin Oncol. 2004;23:20.Google Scholar
- 31.Rowland KM, Suman VJ, Ingle JN, et al. NCCTG 98-32-52: Randomized phase II trial of weekly versus every 3-week administration of paclitaxel, Carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:8.Google Scholar
- 32.Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without wrastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–38.Google Scholar
- 33.Rastogi P, Jeong J, Geyer, et al. CE. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol. 2007;25(18S):513.Google Scholar
- 34.Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.PubMedCrossRefGoogle Scholar
- 35.Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I of II. Vol 23, No. 16S (June 1 Suppl), 2005:556.Google Scholar
- 36.Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis. Breast Cancer Res Treat. 2006;100(Suppl 1):52.Google Scholar
- 37.Halyard MY, Pisansky TM, Solin LJ, et al. Adjuvant radiotherapy and trastuzumab in stage I–IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol. 2006;24(18S):8S.Google Scholar
- 39.Sledge GW, O'Neill A, Thor AD. Adjuvant trastuzumab: Long-term results of E2198. Breast Cancer Res Treat. 2006;100(Suppl 1):S106.Google Scholar
- 40.NCCN Clinical Practice Guidelines in Oncology: Breast cancer. National Comprehensive Cancer Network 2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed May 2007.
- 42.Paik S, Kim C, Jeong J. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol. 2007;25(18S):511.Google Scholar
- 43.Garrison L, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Am J Clin Oncol. 2007;110:489–98.Google Scholar